The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FOREX-Dollar edges down, set for weekly loss; Aussie and Kiwi rise

Fri, 27th Nov 2020 09:03

* Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E

LONDON, Sept 7 (Reuters) - The dollar fell in early London
trading on Friday and was on track for a weekly loss against a
basket of currencies, even as the equity market rally ran out of
steam as sentiment was hurt by doubts about AstraZeneca's
COVID-19 vaccine.

The dollar has fallen more than 2.2% so far this month as
global market sentiment has surged on Joe Biden's U.S. election
victory and news of progress in the development of COVID-19
vaccines, lessening demand for the safe-haven currency.

But sentiment became more mixed after several scientists
raised doubts about the success rate for the vaccine developed
by British drugmaker AstraZeneca.

AstraZeneca had said on Monday that its vaccine was 70%
effective in pivotal trials, and could be up to 90% effective -
the latest in a slew of positive vaccine announcements which had
boosted investor confidence.

"Virus and vaccine news remain the main catalysts for
markets as the US calendar is empty until Monday," ING
strategists wrote in a note to clients.

"All in all, risk sentiment still appears in stabilization
mode, and the dollar may keep oscillating around 2-year lows
(the 92.00 level for DXY) today due to the lack of clear
catalysts and reduced trading volumes," they said.

At 0831 GMT, the dollar was at 91.953 versus a basket of
currencies, down 0.1% on the day and close to its lowest in
three months. Market price-action was limited on Thursday by the
Thanksgiving holiday in the United States, which will be
operating on reduced trading hours on Friday.

The Australian dollar - a liquid proxy for risk - hit its
highest in nearly three months in early London trading and was
up 0.2% at 0.7375 at 0834 GMT.

Australia's second-largest state, Victoria, which was once
the country's COVID-19 hotspot, said on Friday that it has gone
28 days without detecting new infections.

The Kiwi dollar, which is having its best month since late
2013, was up 0.1% on the day at 0.7019.

"Clearly, the biggest single risk for financial markets now
is the failure of vaccines being rolled out smoothly in Q1
2021," wrote MUFG strategist Derek Halpenny.

"The other key risk that also continues to be ignored is the
ongoing surge in COVID infections and deaths in the US," he
said, adding that if President-elect Joe Biden brings in new
lockdown restrictions while the rest of the world is recovering
next year then that provide a further reason to sell the dollar.

Dollar-yen was down 0.2% at 104.03 at 0836 GMT.
China's offshore yuan was on track for its first week of net
losses versus the dollar this month.

The euro was up 0.1% at $1.1925, having shown
little reaction to downbeat comments from the European Central
Bank's chief economist Philip Lane on Thursday.

Elsewhere, the pound was steady at $1.3369 as UK
investors watched Brexit negotiations for signs of progress. The
European Union's chief negotiator said he would travel to London
later on Friday to continue talks. Euro-sterling was steady at
89.22 pence per euro at 0844 GMT.

Bitcoin, which stabilised overnight after wiping off more
than a week's worth of gains on Thursday, was starting to fall
again in early London trading, but less steeply than in the
previous session.
(Reporting by Elizabeth Howcroft; Editing by Simon
Cameron-Moore)

More News
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.